InDex Pharmaceuticals Holding AB Stock price

Equities

INDEX

SE0008966295

Pharmaceuticals

Market Closed - Nasdaq Stockholm 07:48:22 2024-03-28 am EDT 5-day change 1st Jan Change
0.292 SEK -2.01% Intraday chart for InDex Pharmaceuticals Holding AB 0.00% +14.06%
Sales 2023 97.5M 9.12M Sales 2024 * - Capitalization 156M 14.54M
Net income 2023 -95M -8.88M Net income 2024 * -259M -24.22M EV / Sales 2023 1.4 x
Net cash position 2023 * 171M 16.01M Net Debt 2024 * 86.32M 8.07M EV / Sales 2024 * -
P/E ratio 2023
-1.42 x
P/E ratio 2024 *
-0.61 x
Employees 7
Yield 2023 *
-
Yield 2024 *
-
Free-Float 62.47%
More Fundamentals * Assessed data
Dynamic Chart
InDex Pharmaceuticals CEO, CFO to Step Down as Operations Cease MT
Index Pharmaceuticals Holding AB Announces Resignation of Johan Giléus as Deputy CEO CI
InDex Pharmaceuticals Holding AB Announces Resignation of Jenny Sundqvist as CEO, Effective September 26, 2024 CI
InDex Pharmaceuticals Holding AB Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024 CI
InDex Pharmaceuticals Launches Strategic Review Amid Decision to Stop Cobitolimod Development MT
InDex Pharmaceuticals Holding AB Discontinues the Development of Cobitolimod CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
InDex Pharmaceuticals Holding AB Discontinues Cobitolimod Phase III Program CI
InDex Pharmaceuticals Holding AB Announces Composition of the Nomination Committee CI
InDex Pharmaceuticals Obtains South Korean Patent for Inflammatory Bowel Disease Drug Candidate MT
InDex Pharmaceuticals Holding AB Receives New Patent for Cobitolimod in South Korea CI
InDex Pharmaceuticals Holding AB Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude CI
InDex Pharmaceuticals Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news
1 day-2.01%
Current month+5.80%
1 month+4.66%
3 months+18.22%
6 months-60.96%
Current year+14.06%
More quotes
1 week
0.28
Extreme 0.283
0.31
1 month
0.27
Extreme 0.268
0.31
Current year
0.22
Extreme 0.22
0.31
1 year
0.20
Extreme 0.198
0.93
3 years
0.20
Extreme 0.198
1.99
5 years
0.20
Extreme 0.198
12.70
10 years
0.20
Extreme 0.198
12.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 22-12-31
Director of Finance/CFO 59 17-04-30
Chief Tech/Sci/R&D Officer 45 -
Members of the board TitleAgeSince
Director/Board Member 74 15-12-31
Director/Board Member 68 10-12-31
Chairman 72 10-12-31
More insiders
Date Price Change Volume
24-03-28 0.292 -2.01% 1 045 340
24-03-27 0.298 -1.32% 2,613,222
24-03-26 0.302 +1.68% 4,326,865
24-03-25 0.297 +2.41% 2,511,495
24-03-22 0.29 0.00% 3,639,663

Delayed Quote Nasdaq Stockholm, March 28, 2024 at 07:48 am EDT

More quotes
InDex Pharmaceuticals Holding AB is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company is focused in pharmaceuticals development. The Company's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The Company also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn's disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.292 SEK
Average target price
0.535 SEK
Spread / Average Target
+83.22%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock InDex Pharmaceuticals Holding AB - Nasdaq Stockholm